Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases
Second-line treatment for metastatic or locally advanced urothelial cancer (UC) is limited. Immunotherapy is approved as a second-line treatment for metastatic UC. Its use as a first-line agent is limited to patients who are ineligible for cisplatin-based treatments. The fibroblast growth factor rec...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1164368/full |
| _version_ | 1827967067066728448 |
|---|---|
| author | Teng Li Wuyun Hu Lan Jin Xianghua Yin Dongxu Kang Longzhen Piao |
| author_facet | Teng Li Wuyun Hu Lan Jin Xianghua Yin Dongxu Kang Longzhen Piao |
| author_sort | Teng Li |
| collection | DOAJ |
| description | Second-line treatment for metastatic or locally advanced urothelial cancer (UC) is limited. Immunotherapy is approved as a second-line treatment for metastatic UC. Its use as a first-line agent is limited to patients who are ineligible for cisplatin-based treatments. The fibroblast growth factor receptor (FGFR) inhibitor, erdafitinib, can be applied as a third-line approach after the failure of these prior treatments in eligible patients. Therefore, it is especially important to combine limited drugs for second-line treatment of advanced or metastatic UC. Anlotinib is a multiple tyrosine kinase inhibitor agent with both anti-angiogenic and FGFR inhibitory effects. For two patients with advanced and metastatic UC, we combined anlotinib and tislelizumab therapy even though there is no indication of its use. We describe two patients with programmed death ligand-1 (PD-L1)-negative advanced bladder cancer, one with FGFR3 mutation and another with FGFR3 wild type. Both patients had progressed after first-line chemotherapy with gemcitabine and cisplatin. We selected anlotinib in combination with tislelizumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, for second-line treatment. Responses were evaluated as partial remission in both cases, who achieved up to 12 months of progression-free survival with no significant adverse events. Two patients with PD-L1-negative UC underwent second-line therapy using tislelizumab in combination with anlotinib, and the efficacy was better than that of tislelizumab alone. These results suggest that anlotinib may act synergistically with tislelizumab in the treatment of UC. |
| first_indexed | 2024-04-09T17:59:32Z |
| format | Article |
| id | doaj.art-e21302c6b7a443bb9b6a8b30bf2cb16b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T17:59:32Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e21302c6b7a443bb9b6a8b30bf2cb16b2023-04-14T09:48:55ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-04-011310.3389/fonc.2023.11643681164368Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two casesTeng LiWuyun HuLan JinXianghua YinDongxu KangLongzhen PiaoSecond-line treatment for metastatic or locally advanced urothelial cancer (UC) is limited. Immunotherapy is approved as a second-line treatment for metastatic UC. Its use as a first-line agent is limited to patients who are ineligible for cisplatin-based treatments. The fibroblast growth factor receptor (FGFR) inhibitor, erdafitinib, can be applied as a third-line approach after the failure of these prior treatments in eligible patients. Therefore, it is especially important to combine limited drugs for second-line treatment of advanced or metastatic UC. Anlotinib is a multiple tyrosine kinase inhibitor agent with both anti-angiogenic and FGFR inhibitory effects. For two patients with advanced and metastatic UC, we combined anlotinib and tislelizumab therapy even though there is no indication of its use. We describe two patients with programmed death ligand-1 (PD-L1)-negative advanced bladder cancer, one with FGFR3 mutation and another with FGFR3 wild type. Both patients had progressed after first-line chemotherapy with gemcitabine and cisplatin. We selected anlotinib in combination with tislelizumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, for second-line treatment. Responses were evaluated as partial remission in both cases, who achieved up to 12 months of progression-free survival with no significant adverse events. Two patients with PD-L1-negative UC underwent second-line therapy using tislelizumab in combination with anlotinib, and the efficacy was better than that of tislelizumab alone. These results suggest that anlotinib may act synergistically with tislelizumab in the treatment of UC.https://www.frontiersin.org/articles/10.3389/fonc.2023.1164368/fullurothelial cancer (UC)anlotinibfibroblast growth factor receptor (FGFR)tislelizumabPD-L1 |
| spellingShingle | Teng Li Wuyun Hu Lan Jin Xianghua Yin Dongxu Kang Longzhen Piao Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases Frontiers in Oncology urothelial cancer (UC) anlotinib fibroblast growth factor receptor (FGFR) tislelizumab PD-L1 |
| title | Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases |
| title_full | Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases |
| title_fullStr | Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases |
| title_full_unstemmed | Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases |
| title_short | Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases |
| title_sort | case report pd l1 negative advanced bladder cancer effectively treated with anlotinib and tislelizumab a report of two cases |
| topic | urothelial cancer (UC) anlotinib fibroblast growth factor receptor (FGFR) tislelizumab PD-L1 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1164368/full |
| work_keys_str_mv | AT tengli casereportpdl1negativeadvancedbladdercancereffectivelytreatedwithanlotinibandtislelizumabareportoftwocases AT wuyunhu casereportpdl1negativeadvancedbladdercancereffectivelytreatedwithanlotinibandtislelizumabareportoftwocases AT lanjin casereportpdl1negativeadvancedbladdercancereffectivelytreatedwithanlotinibandtislelizumabareportoftwocases AT xianghuayin casereportpdl1negativeadvancedbladdercancereffectivelytreatedwithanlotinibandtislelizumabareportoftwocases AT dongxukang casereportpdl1negativeadvancedbladdercancereffectivelytreatedwithanlotinibandtislelizumabareportoftwocases AT longzhenpiao casereportpdl1negativeadvancedbladdercancereffectivelytreatedwithanlotinibandtislelizumabareportoftwocases |